92 results about "Ovarian carcinomas" patented technology

The invention discloses a BRCA gene susceptibility SNP locus detection composition. The BRCA gene susceptibility SNP locus detection composition comprises a primer of SEQ NO:1-SEQ NO:448. The BRCA gene susceptibility SNP locus detection composition has the advantages that more than two thousand susceptibility SNP loci of a BRCA gene can be detected at one time, for the susceptibility SNP loci relative to breast cancer and ovarian cancer, the detection throughput is high, the specificity is strong, the pollution is not prone to occur, and the safety is high, the detection result has good accuracy and repeatability, and certain auxiliary diagnosis and implication effects are achieved for susceptible population of the breast cancer and the ovarian cancer, especially for crowd with family heredity of the two cancers.

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and / or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and / or decreased toxicity are also provided.

The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is assembled by combining five genomic exons, four very short amino terminal sequences and one extraordinarily large exon. This domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. Additionally, an amino terminal extension is present, which comprises four genomic exons. The amino acid composition of the amino terminal extension was found to be consistent with the amino acid composition of the amino terminal domain. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail. The carboxy terminal also contains a proteolytic cleavage site approximately 50 amino acids upstream from the transmembrane domain, which allows for proteolytic cleavage and release of the CA125 molecule. Any one of the repeat domains has the potential for use as a new gold standard for detecting and monitoring the presence of the CA125 antigen. Further, the repeat domains or other domains, especially the c-terminal to the repeat domain also provide a basis for the development of a vaccine, which would be useful for the treatment of ovarian cancer and other carcinomas where CA125 is elevated.

The invention provides a hydrophobic steroid saponin extract of peltate yam rhizome as well as a preparation method and use thereof. In the invention, in vitro anti-cancer drug experimental study proves that the hydrophobic steroid saponin extract of the peltate yam rhizome has strong growth inhibition activity on cell lines of colon cancer, lung cancer, breast cancer, cervical carcinoma, ovarian cancer, larynx cancer and the like. The extract of peltate yam rhizome has the advantages of wide resource, simple extraction and separation process of saponin, and wide prospect in cancer treatment, thus developing a new anticancer use of a hydrophobic dioscin component in the peltate yam rhizome.